Le Lézard
Classified in: Health, Science and technology
Subject: Conference

CivaTech Oncology selected to present at BIO International Conference


CivaTech Oncology Inc., a leading developer of radioactive cancer therapeutics made a presentation regarding the CivaSheet® at the annual Biotechnology Innovation Organization (BIO) Conference June 14, 2022 in San Diego California. BIO International connects top research and early stage innovations with industry and investors.

CivaTech Oncology's CivaSheet® was supported in development and in clinical trials by National Institutes of Health/National Cancer Institute and the Small Business Innovation Research (SBIR). SBIR, a government program coordinated by the Small Business Administration, plays a valuable role in the start up of new companies developing meaningful products to change lives and improve cancer outcomes. SBIR grants have continued to support small businesses seeking commercialization even in the midst of a global pandemic. Funds from the NCI SBIR have helped CivaSheet® technology gain ground despite the challenging healthcare environment.

Suzanne Babcock, CEO of CivaTech Oncology, indicated that "the role of the SBIR has been pivotal in developing the device and generating a platform that addresses many cancer types including non-small cell lung cancer, pancreatic, colorectal, head and neck, soft tissue sarcomas and more."

CivaSheet®, a novel bio-absorbable, internal radiation treatment, is implanted in less than 30 minutes in the operating room at the time of surgery. It prevents cancer recurrence by delivering a highly targeted dose of radiation directly to the surgical margin where residual cancer cells may remain. Results from clinical trials have shown remarkable improvements in therapeutic outcomes.

CivaSheet® is a flexible, implantable intra-operative radiation therapy device (brachytherapy) which emits unidirectional radiation using integrated gold shielding. This provides a homogenous radiation dose on one side while protecting healthy tissues. This feature is entirely unique to CivaSheet® allowing physicians to safely deliver aggressive radiation doses immediately adjacent to healthy, sensitive tissue. No complications or radiation related side effects have been reported in patients to date.

About CivaTech Oncology:

For more information about CivaSheet or CivaTech Oncology, please visit www.civatechoncology.com or call 919-314-1515 (Randy Harrison).

Taylor RJ, Todor D, Kaplan BJ, Stover W, Fields EC. "CivaSheet intraoperative radiation therapy for pancreatic cancer." Brachytherapy. 2022 Mar-Apr;21(2):255-259. doi: 10.1016/j.brachy.2021.10.007


These press releases may also interest you

at 12:53
Sports nutrition and lifestyle brand Bucked Up launched its Babe by Bucked Up line last October with a desire to create supplements made by women, for women. With its official launch now six months underway, Babe has become a huge sensation and...

at 12:05
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...

at 12:02
On May 1, 2024, Toronto Public Health (TPH) will host Diverse Dialogues: Stigma & Breaking Barriers. The event will bring together distinguished speakers to explore the challenging and thought-provoking topic about how negative labels and biases...

at 11:56
As the demand for cosmetic procedures continues to rise, patients are seeking more advanced and effective options for achieving a youthful and rejuvenated appearance. In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face...

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...



News published on and distributed by: